Drug
Arc Aat
Arc Aat: highest development phase Phase 2, developed by Arrowhead Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Arrowhead Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARC-AAT Injection NCT02900183 | Phase 2 | Alpha-1 Antitrypsin Deficiency |
| ARC-AAT Injection NCT02363946 | Phase 1 | Alpha-1 Antitrypsin Deficiency |
Latest
No recent events.
Follow Arc Aat on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.